#United States #New York #Securities Fraud #PTC Therapeutics #Pomerantz LLP

Pomerantz Law Firm Launches Investigation into PTC Therapeutics

The renowned Pomerantz Law Firm has recently announced its investigation into potential claims on behalf of investors of PTC Therapeutics, Inc. (NASDAQ: PTCT), focusing on allegations of unlawful practices in connection with the company's operations. Investors concerned about the integrity of their investments are encouraged to reach out to the firm for more information.

Background on PTC Therapeutics

PTC Therapeutics operates in the biopharmaceutical sector, with a focus on innovative therapies that target rare diseases. In May 2025, the company released results from its Phase 2 PIVOT-HD study concerning PTC518 (votoplam) for treating Stage 2 and Stage 3 Huntington's disease patients. The trial reportedly met its primary endpoint, demonstrating a significant reduction in blood Huntingtin protein levels.

However, despite these positive results, market analysts raised questions regarding the necessity of a Phase 3 study to conclusively determine whether the treatment truly slows the progression of Huntington's disease. Following this cautious outlook, PTC's stock price saw a significant drop of $9.30 per share, marking an 18.62% decline, closing at $40.65 on the day of the announcement.

Investigative Focus

The firm is building its investigation on possible securities fraud or other unlawful business practices linked to PTC and some of its executives. Investors are urged to participate in this investigation, especially those who feel impacted by the rapid decline in stock prices following the recent news. Danielle Peyton, a representative from Pomerantz, is spearheading this investigation and is available for consultation via phone and email for interested investors.

The Role of Pomerantz LLP

Founded over 80 years ago by Abraham L. Pomerantz, known as a pioneer in securities class action litigation, Pomerantz LLP has established a reputation as a leading force in advocating for shareholders' rights. The firm has successfully recovered substantial damages for investors across various class action litigations, emphasizing its commitment to fighting against corporate fraud and misconduct.

With offices in major cities such as New York, Chicago, Los Angeles, London, and Paris, Pomerantz is well-equipped to take on significant cases related to corporate malfeasance. Their ongoing investigation into PTC Therapeutics highlights their dedication to ensuring justice for investors who might have suffered financial losses due to unethical practices.

Conclusion

As the Pomerantz Law Firm continues its probe, investors will be keenly watching to see how this investigation unfolds. If you believe you have been affected by the actions or statements made by PTC Therapeutics, consider reaching out to Pomerantz for guidance and support. With their expertise in securities law, they are well-positioned to help affected parties navigate this challenging environment. Remember, taking action at this stage could be crucial in protecting your investments and seeking potential recovery.